Clinical Trial Update: A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 [Phase 1]

View source ↗

Summary

This clinical trial update reports that Sarepta Therapeutics' gene transfer therapy Delandistrogene moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Delandistrogene moxeparvovec (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: TERMINATED